Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells-Reference-Cited by-同舟云学术

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Published:2016-11 Issue:7629 Volume:539 Page:443-447
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

De Henau Olivier,Rausch Matthew,Winkler David,Campesato Luis Felipe,Liu Cailian,Cymerman Daniel Hirschhorn,Budhu Sadna,Ghosh Arnab,Pink Melissa,Tchaicha Jeremy,Douglas Mark,Tibbitts Thomas,Sharma Sujata,Proctor Jennifer,Kosmider Nicole,White Kerry,Stern Howard,Soglia John,Adams Julian,Palombella Vito J.,McGovern Karen,Kutok Jeffery L.,Wolchok Jedd D.,Merghoub Taha

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/nature20554.pdf

Reference25 articles.

1. Khalil, D. N., Smith, E. L., Brentjens, R. J. & Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273–290 (2016)

2. Coussens, L. M., Zitvogel, L. & Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 339, 286–291 (2013)

3. Gajewski, T. F., Schreiber, H. & Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014–1022 (2013)

4. Schmid, M. C. & Varner, J. A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. 2010, 201026 (2010)

5. Diaz-Montero, C. M., Finke, J. & Montero, A. J. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin. Oncol. 41, 174–184 (2014)

Cited by 686 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer;Molecular Cancer;2024-09-06

2. Targeting macrophages to reprogram the tumor immune microenvironment;Blood Science;2024-08-15

3. Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy;Journal of Translational Medicine;2024-08-09

4. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08

5. Targeting PI3K-gamma in myeloid driven tumour immune suppression: a systematic review and meta-analysis of the preclinical literature;Cancer Immunology, Immunotherapy;2024-08-06